Signaturefd LLC Buys 1,052 Shares of Fresenius Medical Care AG (NYSE:FMS)

Signaturefd LLC grew its stake in Fresenius Medical Care AG (NYSE:FMS) by 16.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,393 shares of the company’s stock after acquiring an additional 1,052 shares during the period. Signaturefd LLC’s holdings in Fresenius Medical Care were worth $167,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Fresenius Medical Care during the 3rd quarter worth approximately $420,000. Charles Schwab Investment Management Inc. grew its position in shares of Fresenius Medical Care by 11.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock worth $472,000 after buying an additional 2,233 shares during the period. Glenmede Trust Co. NA acquired a new stake in shares of Fresenius Medical Care during the 3rd quarter worth approximately $271,000. Verition Fund Management LLC acquired a new stake in shares of Fresenius Medical Care during the 3rd quarter worth approximately $237,000. Finally, Quantinno Capital Management LP grew its position in shares of Fresenius Medical Care by 78.9% during the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after buying an additional 48,554 shares during the period. 8.37% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Truist Financial lifted their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Finally, Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd.

Fresenius Medical Care Stock Down 1.4 %

Shares of NYSE FMS opened at $24.29 on Friday. The stock has a market cap of $14.25 billion, a P/E ratio of 20.07, a P/E/G ratio of 0.76 and a beta of 0.99. The firm has a 50 day moving average price of $23.86 and a 200 day moving average price of $22.37. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. Fresenius Medical Care AG has a 52-week low of $17.93 and a 52-week high of $25.25.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.